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Umbilical Cord Blood Transplantation (UCBT) for
Hematologic Malignancies
Michael J. Burke,1 Rachel Isaksson Vogel,2 Sanyukta K. Janardan,1 Claudio Brunstein,3
Angela R. Smith,1 Jeffrey S. Miller,3 Daniel Weisdorf,3 John E. Wagner,1 Michael R. Verneris1Rapid lymphocyte recovery after bone marrow or peripheral blood transplantation is associated with
improved survival. However, the impact of early lymphocyte recovery has not been examined after umbilical
cord blood transplant (UCBT). We evaluated lymphocyte recovery in 360 consecutive patients with hema-
tologic malignancy that underwent UCBT between 2001 and 2007. Uniform myeloablative (MA), reduced
intensity conditioning (RIC) and graft-versus-host disease prophylaxis regimens were used. In multivariate
analysis, an absolute leukocyte count (ALC) .200  106/L at day 30 (n 5 73) after MA conditioning was
associated with superior 2-year overall survival (OS) (73% versus 61%; P 5 .02) (relative risk [RR]: 2.29;
95% confidence interval [CI]: 1.15-4.56), progression-free survival (PFS) (68% versus 54%; P 5 .05) (RR:
1.96; 95% CI: 0.99-3.86) and less transplant-related mortality (8% versus 28%, P\.01) (RR: 4.38; 95% CI:
1.65-11.60) compared to#200  106/L (n5 43). Similarly, an ALC.200  106/L at day 42 (n5 105) after
RIC was associated with superior 2-year OS (59% versus 41%, P\.01) (RR: 2.10; 95% CI: 1.3-3.41) and PFS
(46% versus 36%, P5 .05) (RR: 1.58; 95% CI: 1.01-2.49) compared to#200 106/L (n5 55). There was no
significant relationship between ALC and relapse. Rapid lymphocyte recovery early after UCBT predicts
better survival in patients with hematologic malignancies.
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Umbilical cord blood, Reduced-intensity conditioningINTRODUCTION
Umbilical cord blood (UCB) has become an in-
creasingly used stem cell source for the treatment of
hematologic malignancies in both children and adults.
Like other unrelated graft sources, posttransplant
complications including treatment-related mortality
(TRM) and relapse remain barriers to patient survival.
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6/j.bbmt.2010.08.022plantation are delayed compared to other stem cell
sources, such as bone marrow (BM) or peripheral
blood (PB), and therefore may play a role in determin-
ing transplant outcomes [1-5].
Prior studies in BM and PB transplant recipients
show that the early differences in absolute lymphocyte
count (ALC) are predictive of survival in patients with
hematologic malignancies [6-11]. To date, there is
little data available on lymphocyte recovery and its
influence on umbilical cord blood transplant (UCBT)
outcomes. Although low ALC appears to be associated
with higher risk of infections [12], and lymphocyte func-
tion may be impaired after UCBT [13], a relationship
between the kinetics of ALC recovery and survival has
not yet been investigated. Based on the prior studies in
BM and PB transplant recipients showing inferior
survival [6-11], we hypothesized that delayed recovery
of ALC after UCB transplantation might be associated
with inferior transplant outcomes. We therefore
evaluated whether differences in ALC early after
UCBT were associated with transplant outcomes in
patients with hematologic malignancies and assessed
differences after myeloablative (MA) and reduced-
intensity conditioning (RIC) regimens.831
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Patients
This study included 360 consecutive patients with
a hematologic malignancy who underwent either MA
or RIC unrelated donor UCBT at the University of
Minnesota between 2001 and 2007. Patient demo-
graphics are listed in Table 1. Clear differences
between these 2 populations were present, including
age, time from diagnosis to transplant, disease, single
versus double UCB transplantation, and HLA dispar-
ity (likely because of the addition of a second unit).
Thirty-eight patients were excluded based on not hav-
ing an available ALC reported (because of early death)
or failed engraftment. All patients and/or guardians
provided informed consent according to the principles
of the Declaration of Helsinki prior to transplantation.
Patient demographics and clinical outcomes data were
prospectively collected and available from the Univer-
sity of Minnesota Bone Marrow Transplant Database.
UCB Unit Selection and Characteristics
Methods of HLA typing and UCB unit selection
have been detailed elsewhere [14,15]. Briefly, UCB
units were typed with the recipient at intermediate
resolution for HLA-A and -B and at allele level for
HLA-DRB1. Other HLA loci were not considered in
the selection algorithm. UCB units were selected if
they were #2 locus HLA-mismatched with the recip-
ient. The choice to receive 1 or 2 UCB units was based
on cell dose available to the patient. Prior to 2002, the
minimum acceptable cell dose for a single unit was
1.5  107 nucleated cells (NC) per kilogram (kg) and
after 2002 the minimum cell dose was 2.5  107/kg.
After 2003, the target cell dose was $3.0  107 NC/
kg for those with HLA matched (ie, 6/6) units and
$4.0  107/kg for those with HLA mismatched
(ie, 4-5/6) units. If an UCB unit with the minimum
cell dose was not available, the patient was trans-
planted with 2 partially HLA matched UCB units
that were\2 locus HLA-mismatched with each other,
as previously described [15-17].
Conditioning Regimens, Graft-versus-Host
Disease (GVHD) Prophylaxis, and
Supportive Care
The majority of patients from the MA group (n 5
111, 84%) received conditioning with cyclophospha-
mide (Cy) (120 mg/kg), total-body irradiation (TBI)
(1320 cGy) and fludarabine (Flu) (75 mg/m2), with
the remaining patients receiving either the same Cy/
TBI (without fludarabine, n 5 17, 13%) or a busul-
fan-containing preparative regimen (n 5 5, 4%).
GVHD prophylaxis was cyclosporine (CSA)-based
(CSA and mycophenolate mofetil [MMF] [n 5 111]
and CSA/prednisone/antithymocyte globulin [ATG][n5 22]) for a minimum of 180 days after UCB trans-
plantation as previously described [14,17]. For the
patients who received RIC allo-HCT, the majority
(n 5 176, 93%) received conditioning with Cy (50
mg/kg), TBI (200 cGy) and Flu (200 mg/m2) [18].
GVHD prophylaxis was CSA/MMF. The reason for
using a RIC regimen was either because of age .45
years, concurrent infection or poor performance
status.
All UCB units were thawed according to the
methods of Rubinstein et al. [19] and infused after
hydration and premedication with acetaminophen and
Diphenhydramine.UCBunits were infused shortly after
thawing/washing, and for patients receiving 2 units, they
were infused sequentially within 30 minutes of each
other. For double UCB unit transplant, order of unit
infusion was random. Granulocyte-colony stimulating
factor (G-CSF) (5 mg/kg/day) was administered to all
patients from day 1 until an absolute neutrophil count
(ANC) $2.5  109/L was achieved for 2 consecutive
days. All patients received Pneumocystis jiroveci pneumo-
nia prophylaxis with trimethoprim-sulfamethaxole or
pentamidine for the first 12 months of transplantation.
Viral prophylaxis included acyclovir if seropositive for
herpes simplex or cytomegalovirus prior to transplant.
Cytomegalovirus (CMV) surveillance was performed
weekly on peripheral blood with ganciclovir treatment
at the time of positive antigen or polymerase chain reac-
tion (PCR) testing.
GVHD was diagnosed clinically with histologic
confirmation when possible. Staging was based upon
published criteria [20] and treatment of acute
GVHD (aGVHD) clinical stage II or greater was
with methlyprednisolone ($48 mg/m2 intravenously
or oral equivalent) daily for a minimum of 2 weeks
prior to a taper over 8 weeks.Statistical Analysis
Kaplan-Meier estimates for 2-year overall survival
(OS) and progression-free survival (PFS) are reported
[21]. Cumulative incidence of relapse and transplant
related mortality (TRM) at 2 years were calculated
by treating deaths from other causes and relapse, re-
spectively, as competing risks [22]. Statistical compar-
isons of the time-to-event curves for OS and PFS were
compared by the log-rank test and for relapse and
TRM by Gray’s test. Event times were calculated
from the date of transplantation to the event or the
date of last contact. OS, PFS, and time to relapse
were censored at 4 years and TRM was censored at 2
years for all patients.
ALC cutoffs of 150, 200, 250, and 300  106/L at
21, 30, 42, 60, and 100 days after UCBT were evalu-
ated in univariate models for each outcome; these cut-
offs were chosen for comparison with previously
published data on ALC outcomes in allogenic
Table 1. Patient Characteristics
MAC HCT RIC HCT
n (%) n (%) P-Value*
Number of patients 147 213
At least 1 ALC reported and engrafted 133 (90.5) 189 (88.7)
Follow-up .0827
Median (range) years 2.0 (0.12-6.9) 1.3 (0.1-7.2)
Age at time of HCT <.0001
Median (range) years 17.4 (0.5-45.2) 50.9 (3.4-69)
Time from Dx to HCT .0030
Median (range) years 0.9 (0.2-10.1) 1.4 (0.1-20.6)
Gender .8499
Male 76 (57.1) 110 (58.2)
Transplant type <.0001
Single 50 (37.6) 21 (11.1)
Double 83 (62.4) 168 (88.9)
Prep <.0001
BU,CY 1 (0.8)
BU,MEL 4 (3.0)
CY,FLU,TBI 111 (83.5) 176 (93.1)
CY,TBI 17 (12.8) 1 (0.5)
BU,FLU,TBI 12 (6.4)
Disease <.0001
ALL/ AML/ CML 59 (44.4)/74 (55.6)/0 16 (8.5)/62 (32.8)/8 (4.2)
Leukemia NOS/MDS/malignancy 29 (15.4)
Lymphoma 65 (34.4)
Myeloproliferative Disease 9 (4.8)
Disease status at transplant N/A
PIF resistant 2 (1.5)
CR1 58 (43.6)
CR2 59 (44.4)
CR3 9 (6.8)
REL 2 5 (3.8)
Standard risk 69 (36.5)
High risk 120 (63.5)
HLA match† .0132
4 64 (48.1) 122 (64.6)
5 56 (42.1) 55 (29.1)
6 13 (9.8) 12 (6.4)
Acute GVHD max grade .2525
None/1 66 (49.6) 106 (56.1)
2-4 67 (50.4) 83 (43.9)
Chronic GVHD .6841
Yes 25 (18.8) 39 (20.6)
Dx indicates diagnosis; HCT, hematopoietic cell transplantation; leukemia NOS, leukemia not otherwise specified; MDS, myelodysplastic syndrome; ma-
lignancy, other malignancy; GVHD, graft-versus-host disease; ALC, absolute lymphocyte count; BU, busfultan; CY, cyclophosphamide; MEL, melphalan;
FLU, fludarabine; TBI, total-body irridation; ALL, acute lymphoblastic leukemia; AML, acute myelogenous leukemia; CML, chronic myeloid leukemia; PIF,
primary induction failure; CR, complete remission; RIC, reduced-intensity conditioning.
*Wilcoxon 2-sample tests and chi-squared test/Fisher’s Exact Test as appropriate.
†HLA for single transplant or minimum HLA for double transplant patients.
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tients [6,8,10]. Multivariate regression analyses with
Cox regression and the Fine and Gray competing
hazards methods were used as appropriate [23,24].
Models were fit for each ALC cutoff while also
adjusting for gender, age at transplant, total infused
nucleated cell dose, colony-forming unit-granulo-
cyte-macrophage (CFU-GM), infused CD3 and
CD34 cell doses, time from initial diagnosis to trans-
plant, number of umbilical cord blood units trans-
planted, HLA-match (HLA for single transplant or
minimum HLA for double transplant patients), recip-
ient CMV status, and the development of aGVHD
(included as a time-dependent covariate). Acute
GVHD andHLA-match were explored inmultivariatemodels of relapse and TRM and were found to be not
significant; therefore, they were not adjusted for in the
final relapse and TRM models to ensure convergence.
All reported P-values are from adjusted models unless
otherwise noted.
The total number of confirmed bacterial, fungal,
and viral infections among all patients was evaluated
and the total number of early and late infections per
patient determined; defined as before (early) and after
(late) the ALC cutpoint day of interest. Patients were
categorized into 3 groups: those with 0 infections, 1
infection or $2 infections during the particular time
period. The number of patients in each group was
compared by the ALC cutpoint using Fisher’s Exact
test.
Figure 1. OS and TRM following myeloablative UCB transplantation based on ALC. (A) The estimated PFS for these 2 groups (day 30 ALC. or#200)
at 2 years was 73% and 61%, respectively (P5 .02). (B) The cumulative incidence of TRM for these 2 groups (day 30 ALC. or#200) at 2 years was 8%
and 28%, respectively (P\.01).
834 Biol Blood Marrow Transplant 17:831-840, 2011M. J. Burke et al.As the primary aim of this analysis was to identify
the earliest time that an ALC may be predictive of
outcomes, we reported the earliest day and most pre-
dictive ALC of outcome measures (P-values\.10 for
multiple outcomes) in our results for both MA and
RIC cohorts, which were analyzed separately. Patient
and transplant characteristics were compared by
ALC cutoff using chi-squared and Fisher exact tests
for categoric data and the Wilcoxon rank-sum test
for continuous data. All analyses were performed using
SAS version 9.1 and R version 2.7.RESULTS
Patients
Patient ALCs were abstracted from medical re-
cords on or within 3 days of 21, 30, 42, 60, and 100
days after UCBT. ALC were recorded as missing at
a particular time point if the white blood cell count
(WBC) was\0.5  109/L, as no manual differential
counts were performed during severe leukopenia. If
patients relapsed prior to 100 days, their ALC was in-
cluded only up to the date of relapse. Of the 147 (41%)
patients who received an MA regimen, 133 (90%) had
neutrophil recovery and at least 1 ALC recorded. As
shown in Table 1, 59 (44%) of the 133 patients had
ALL and 74 (56%) had acute myelogenous leukemia
(AML). Prior toUCBT, 58 (44%) patients were in first
complete remission (CR1), 59 (44%) CR2, 9 (7%)
CR3, and the remaining 7 patients were either primary
induction failure (PIF) (n 5 2) or in relapse (n5 5).
Of the total patients, 213 (59%) patients received
an RIC regimen. One hundred eighty-nine (89%)
had neutrophil recovery and at least 1 ALC recorded.
As shown in Table 1, 108 had leukemia (AML n 5
62; acute lymphoblastic leukemia (ALL) n 5 16;
chronic myelogenous leukemia [CML] n 5 8; other
leukemia/myelodysplastic syndrome (MDS) n 5 22),65 lymphoma (Hodgkins disease [HD] n 5 24; non-
Hodgkins lymphoma [NHL] n5 41), and the remain-
ing 16 patients had myeloproliferative diseases (n5 9)
or other hematologic malignancy (n 5 7).
Myeloablative UCBT
At day 30 after MAUCB transplant patients with an
ALC#200  106/L had significantly inferior OS (61%
versus 73%; P 5 .02), PFS (54% versus 68%; P 5 .05),
and greater TRM (28% versus 8%; P # .01) at 2 years
compared to patients with an ALC .200  106/L
(Figure 1A and B and Table 2). Causes of TRM for
patients #200  106/L were multiorgan failure (n 5
7), infection (n 5 4; fungal n 5 3, viral n 5 1), hemor-
rhage (n5 1), and aGVHD (n5 1) compared to infec-
tion (n 5 2; fungal n 5 1, bacterial n 5 1), aGVHD
(n 5 2), multiorgan failure (n 5 1), and secondary late
graft failure (n5 1) for those.200106/L. In contrast,
ALC#200 106/L at day 30 was not significantly asso-
ciated with risk of relapse (18% versus 24%, P5 .72). In
multivariate analysis, an ALC #200  106/L remained
the only independent predictor of worse survival, PFS,
and higher TRM after adjusting for gender, age at
transplant, total infused cell dose, CFU-GM, infused
CD3 and CD34 cell dose, time from initial diagnosis to
transplant, single versus double umbilical cord blood
transplant, HLA-match, recipient CMV status, and de-
velopment of aGVHD (as a time-dependent covariate)
(Table 2).
Pretransplant patient and graft characteristics were
compared across patients with a low or high ALC to
determine whether these parameters were associated
with day 30 ALC. Although patients with an ALC
#200  106/L at day 30 were more likely to receive
2 UCB units (P5 .05) and have slightly slower neutro-
phil recovery (22.8 versus 20.9 days, P 5 .054), there
was no differences in age at transplant, disease status,
preparative regimen, HLA-match, infused CD3 or
CD34 cell dose, or time to neutrophil engraftment
Table 2. Multivariate Analysis of Outcomes
Endpoint Relative Risk (95% CI) P-Value
MA Patients
Overall survival*
Day 30 ALC .02
#200  106/L 2.29 (1.15, 4.56)
>200  106/L‡ 1.0
Progression-free survival*
Day 30 ALC .05
#200  106/L 1.96 (0.99, 3.86)
>200  106/L‡ 1.0
Relapse†
Day 30 ALC .72
#200  106/L 0.84 (0.32, 2.20)
>200  106/L‡ 1.0
Treatment-related mortality†
Day 30 ALC <.01
#200  106/L 4.38 (1.65, 11.60)
>200  106/L‡ 1.0
RIC patients
Overall survival*
Day 42 ALC <.01
#200  106/L 2.10 (1.30, 3.41)
>200  106/L‡ 1.0
CFU-GM (per 0.01 increase) 1.11 (1.00, 1.23) .04
Progression-free survival*
Day 42 ALC .05
#200  106/L 1.58 (1.01, 2.49)
>200  106/L‡ 1.0
CFU-GM (per 0.01 increase) 1.14 (1.03, 1.26) .01
CD3 (per 0.01 increase) 0.95 (0.90, 1.00) .05
CD34 (per unit increase) 0.39 (0.16, 0.95) .04
Relapse†
Day 42 ALC .63
#200  106/L 1.16 (0.63, 2.13)
>200  106/L‡ 1.0
Treatment-related mortality†
Day 42 ALC .24
#200  106/L 1.54 (0.75, 3.18)
>200  106/L‡ 1.0
CI indicates confidence interval; ALC, absolute lymphocyte count;
RIC, reduced-indensity conditioning; CFU-GM, colony forming unit-
granulocyte macrophage.
*Variables included in model: ALC cut-point of interest, gender, age at
transplant, total cell dose, CFU-GM, infused CD3 and CD34 cell dose,
time from initial diagnosis to transplant, single versus double umbilical
cord blood transplant, HLA-match, recipient CMV status and develop-
ment of acute GVHD (as a time-dependent covariate).
†Variables included in model: ALC cut-point of interest, gender, age at
transplant, total cell dose, CFU-GM, infused CD3 and CD34 cell dose,
time from initial diagnosis to transplant, single versus double umbilical
cord blood transplant and recipient CMV status.
‡Reference group; The ALC cut-point and all other variables with
P-values <.05 are reported for each model.
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tweenMA patients, there were significantly more early
infections (\30 days post-HCT) in patients with an
ALC#200 106/L at day 30, but no significant differ-
ence in the number of late infections (days 31-100
post-HCT) based on day 300 ALC (Figure 2A and B).RIC Allogeneic-HCT
The day 30 ALC #200  106/L after RIC UCB
transplant did not show a significant difference in 2-
year OS (48% versus 54%; P5 .19), PFS (40% versus
41%; P 5 .35), relapse (38% versus 34%; P 5 .81) orTRM (22% versus 25%; P5 .57) compared to patients
.200  106/L. However, the day 42 ALC was predic-
tive. Patients with a day 42 ALC #200  106/L had
significantly inferior 2-year OS (41% versus 59%;
P\ .01) and PFS (36% versus 46%; P5 .05) compared
to patients .200  106/L (n 5 109) (Figure 3A and
Table 2). There was no significant difference in either
TRM (29% versus 19%; P 5 .24) (Figure 3B) or dis-
ease recurrence (44% versus 31%, P 5 .63) based on
day 42 ALC # or .200  106/L. Causes of TRM
for patients #200  106/L at day 42 were multiorgan
failure (n5 8), infection (n5 5; fungal n5 2, bacterial
n5 2, viral n5 1), GVHD (n5 1), hemorrhage (n5 1)
and secondary malignancy (n5 1) compared to multi-
organ failure (n5 5), infection (n5 4; viral n5 4), and
GVHD (n 5 3) for those .200  106/L.
In comparing the incidence of infections between
RIC patients, there was no significant difference in
the number of early (#42 days post-HCT) or late
(days 43-100 post-HCT) infections based on the day
42 ALC (Figure 2). In multivariable analysis, after ad-
justing for gender, age at transplant, total infused cell
dose, CFU-GM, infused CD3 and CD34 cell dose,
time from initial diagnosis to transplant, single versus
double umbilical cord blood transplant, HLA-match,
recipient CMV status, and development of aGVHD
(as a time-dependent covariate), an ALC #200 
106/L remained an independent predictor of worse
survival and PFS (Table 2). Like the MA group, there
were no significant differences in the pretransplant and
graft characteristics of RIC patients with day 42 ALC
# or .200  106/L (Table 4).DISCUSSION
Therehave been a number of improvementsmade in
the field of UCB transplantation over recent years, par-
ticularly in defining a critical infused cell dose needed
for sustained neutrophil recovery and in developing
approaches to overcome this limitation [15,25-27].
Despite the progress in recognizing a critical cell dose
for engraftment, TRM and relapse remain significant
causes of treatment failure for UCB recipients. TRM is
especially distressing because it occurs in patients that
might otherwise be cured from their disease. The
ability to identify patients at increased risk for early
death could lead to interventions directed toward
preventing these negative outcomes. This single
institution analysis of 360 patients who received UCB
transplantation for hematologic malignancies, shows
that early rapid lymphocyte recovery, after either
myeloablative or RIC transplantation is an independent
parameter associated with superior survival.
In this analysis, patients who received either aMA or
RIC UCB transplant and had an ALC.200  106/L at
day 30 or 42, respectively, had superior OS and PFS.
Table 3. Pretransplant and Graft Characteristics of Patients with ALC # or >200 at D+30 following Myeloablative Conditioning
ALC #200 at Day 30 n (%) ALC >200 at Day 30 n (%) P-Value*
Total patients 46 (38.7) 73 (61.3)
Gender .90
Male 27 (58.7) 42 (57.5)
Transplant type .05
Single 13 (28.3) 34 (46.6)
Double 33 (71.7) 39 (53.4)
Prep .90
BU, CY 0 (0.0) 1 (1.4)
BU, MEL 1 (2.2) 3 (4.1)
CY,FLU,TBI 40 (87) 59 (80.8)
CY,TBI 5 (10.9) 10 (13.7)
Disease status at transplant .96
PIF resistant 0 (0.0) 1 (1.4)
CR1 17 (37) 31 (42.5)
CR2 23 (50) 33 (45.2)
CR3 4 (8.7) 5 (6.9)
REL 2 2 (4.3) 3 (4.1)
HLA match† .53
4 25 (54.4) 33 (45.2)
5 16 (34.8) 33 (45.2)
6 5 (10.9) 7 (9.6)
ALC #200 at Day 30 ALC >200 at Day 30
P-Value§N Median (Min, Max) N Median (Min, Max)
Cell dose (Cells  108/kg)‡ 46 0.39 (0.2, 1.40) 73 0.43 (0.21, 1.39) .30
CFU-GM (CB  106/kg)‡ 43 0.05 (0.01, 0.13) 73 0.07 (0.05, 1.04) .59
CD3 (CB  106/kg)‡ 46 0.15 (0.05, 0.24) 73 0.14 (0.04, 0.32) .70
CD34 (CB  106/kg)‡ 46 0.49 (0.10, 1.83) 73 0.51 (0.09, 3.12) .36
Days from DX to TX 46 444.5 (67, 3696) 73 388.0 (68, 3096) .43
Time to donor ANC Engraftment (days) 46 22.8 (11, 38) 73 20.9 (11, 40) .054
Dx indicates diagnosis; BU, busfultan; CY, cyclophosphamide; MEL, melphalan; FLU, fludarabine; TBI, total-body irridation; ANC, absolute neutrophil
count; PIF, primary induction failure; CR, complete remission; ALC, absolute lymphocyte count; CFU-GM, colony forming unit-granulocyte macrophage;
CB, cord blood; TX, treatment.
*Chi-squared test/Fisher’s Exact Test as needed.
†HLA for single transplant or minimum HLA for double transplant patients.
‡Defined as total dose (for double cord transplant, sum of both donors).
§Wilcoxon 2-sample test.
836 Biol Blood Marrow Transplant 17:831-840, 2011M. J. Burke et al.Similar findings of improved outcomes for BM and
PBSC recipients have been reported [6-11], but this issue
has not yet been examined in UCB transplantation. The
exact explanation for these findings is unknown, but
may reside in the cells that make up the ALC at these
early time points. NK cells recover to normal amounts
rapidly after transplant [28];however, these cells are func-
tionally impaired [29]. Despite this, 2 prior studies corre-
latinghighALCwith improved transplantoutcomeshave
implicated natural killer (NK) cells as being significantly
associated with improved outcomes [30,31]. Thus,
perhaps the numbers of NK cells in the graft or levels
of endogenous cytokine (ie, IL-15) after transplant may
differentially influence NK expansion and account for
these findings. Alternatively, even though the number
of T cells at days 30 to 60 after transplant are low, recon-
stitution is actively occurring and rapid recovery of
the T cell compartment might also account for these
observations. Both thymic independent (homeostatic
proliferation) and dependent pathways of T cell reconsti-
tution have been described (reviewed in [32]). The earlyincreases in T cells after transplant are thought to be
mainly because of homeostaticTcell proliferation,where
a limited repertoire of T cells emerge in response to
alloantigen stimulation and high serum cytokine concen-
trations. Whether these T cells are protective against
relapse or infectious organisms remains an open question
in humans, but both have been hypothesized [32,33].
Perhaps in support of this, Hamza et al. showed that
patients with rapid lymphoid recovery after UCBT and
MUD BMT had a lower risk of infections [12]. In con-
trast, interferon (IFN)-gproducingCD81CMVreactive
T cells could be detected in the blood of UCB recipients
early after transplant (week 8), but their appearance did
not correlate withCMVcontrol [34]. Alternatively, rapid
lymphocyte recovery may reflect a more robust thymic-
dependent T cell production. In support of this, Koman-
duri et al. [13] showed thatUCB recipients who had high
numbers of CD41 T cells that coexpressed CCR71
(found on na€ıve and central memory cells) at day 30
UCB had superior survival, suggesting that new T cell
formation and intact immune responses were critical to
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Figure 2. Early and late infections after MA and RIC conditioning andUCB transplantation. The number of infections occurring in patients either before
or after the ALC cut-point after MA and RIC conditioning are depicted. Dark stippled bars represent a single infection during the time period and light
stippled bars represent 2 or more infections. (A) The number of infections at #30 days after MA conditioning for patients with ALC #200 or .200
(P5.01). (B) The number of infections at 30-100 days after MA conditioning for patients with ALC#200 or.200 (P5.10). (C) The number of infections
at#42 days after RIC conditioning for patients with ALC#200 or.200 (P5.54). (D) The numberof infections at 42-100 days after RIC conditioning for
patients with ALC #200 or .200 (P 5 .11).
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#200  106/L had significantly more early infections
compared to patients .200  106/L, but this was not
seen for late infections or for RIC patients (early or late
infections) based on their day 42 ALC. Unfortunately,
for a significant proportion of patients in our study, we
do not have detailed lymphocyte subset data available to
determine the composition of the patient’s ALC, and
this will be addressed in future studies.
Several prior studies that report the benefit of high
ALC early after transplant show that the improvement
in survival is because of lower relapse rates [6-11]. For
instance, in studies of patients transplanted with ALL
[10], AML [9], or a mixture of hematologic diseases
[11], a high day 21 ALC was strongly correlated with
a reduction in relapse and an improved DFS following
matched sibling donor transplant. Similar results were
shown by Savani et al. [31] for T cell-depleted sibling
donor transplants for AML at day 30, but not for
ALL. These findings by Savani et al. [31] prompted us
to perform a similar subgroup analysis (based on disease
type) in our myeloablative and RIC patient cohorts.
However, for both subgroups of diseases in patients un-
dergoing myeloablative (ALL and AML) or RIC UCB
transplantation (leukemia/MDS and lymphoma), we
were unable to identify a significant impact of ALC ondisease relapse inmultivariate analysis (data not shown).
In contrast to other reports on early lymphocyte
recovery following BM or peripheral blood stem cell
(PBSC) transplantation [6-11,31], our results in UCB
transplantation show that a low ALC after MA allo-
HCT was associated with significantly higher TRM,
with no impact on relapse. The early TRM identified
in these patients may have been a competing risk to re-
lapse, thus explaining these results. Although it is tempt-
ing to speculate that high ALC early after transplant is
somehow related to graft-versus-tumor reactions, the
association of ALC on relapse is not limited to the
allogeneic graft-versus-tumor effect, because similar
findings have been found after autologous transplant
for non-Hodgkin’s lymphoma [35], Hodgkin’s disease
[36], multiple myeloma [37], and Ewing sarcoma [38].
All prior studies investigating ALC on allo-HCT
outcomes have been in the myeloablative setting [6-11].
The time to lymphocyte recovery in our myeloablative
UCB recipients are relatively similar to the studies in
BM or PBSC recipients reported by others [6,7,9,10].
This is remarkable considering that UCB recipients
receive 10 to 50 fewer mononuclear cells (MNCs)/
kg, and that these cells have been cryopreserved and
thawed, which negatively affects viability. Thus, these
results might suggest that the proliferation kinetics
Figure 3. OS and TRM following RIC conditioning and UCB transplantation based on ALC. (A) The estimated PFS for these 2 groups (day 42 ALC. or
#200) at 2 years was 46% and 36%, respectively (P5 .05). (B) The cumulative incidence of TRM for these 2 groups (day 42 ALC. or#200) at 2 years
was 19% and 29%, respectively (P 5 .24).
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differ compared to BM/PBSC.
Here, we also report the first large series of ALC
data in patients undergoing RIC conditioning (n 5
189). In these patients, day 42 was the first time that
ALC was significantly predictive for transplant associ-
ated outcomes. Based on our prior studies, themajority
of patients show full donor lymphocyte chimerism atTable 4. Pretransplant andGraft Characteristics of PatientswithAL
ALC #200 at Day 42 n (%)
Total patients 60 (34.3)
Gender
Male 39 (65.0)
Transplant type
Single 6 (10.0)
Double 54 (90.0)
Prep
BU, FLU,TBI 4 (6.67)
CY,FLU,TBI 56 (93.3)
CY,TBI 0 (0.0)
Disease status at transplant
Standard 16 (26.7)
High risk 44 (73.3)
HLA match†
4 39 (65.0)
5 18 (30.0)
6 3 (5.0)
ALC #200 at Day 42
N Median (Min,
Cell dose (Cells  108/kg)‡ 60 0.34 (0.11,
CFU-GM (CB  106/kg)‡ 55 0.04 (0.01,
CD3 (CB  106/kg)‡ 58 0.12 (0.02,
CD34 (CB  106/kg)‡ 60 0.40 (0.11,
Days from DX to TX 60 622.5 (70, 75
Time to donor ANC Engraftment (days) 60 16.5 (5, 39)
RIC indicates reduced-intensity conditioning; ANC, absolute neutrophil coun
MEL, melphalan; FLU, fludarabine; TBI, total-body irridation; CFU-GM, colony f
phocyte count.
*Chi-squared test/Fisher’s Exact Test as needed.
†HLA for single transplant or minimum HLA for double transplant patients.
‡Defined as total dose (for double cord transplant, sum of both donors).
§Wilcoxon 2-sample test.this time point [18]. Although the kinetics of immune
recovery are relatively similar betweenMAandRIC re-
cipients [39], an explanation for the difference in time
(day 30 versus day 42) between MA and RIC in terms
of an ALC of #200  106/L predicting outcome may
be the result of residual host cells competing with lym-
phoid growth factors in RIC patients. Alternatively,
after RIC, the niches for stem cells and lymphoidC# or >200 atD+42 followingReduced-IntensityConditioning
ALC >200 at Day 42 n (%) P-Value*
115 (65.7)
.28
65 (56.5)
.79
13 (11.3)
102 (88.7)
.67
5 (4.4)
109 (94.8)
1 (0.9)
.08
46 (40.0)
69 (60.0)
.84
74 (64.4)
32 (27.8)
9 (7.8)
ALC >200 at Day 42
P-Value§Max) N Median (Min, Max)
0.82) 115 0.37 (0.15, 1.40) .46
0.26) 105 0.05 (0.00, 0.16) .30
0.30) 115 0.13 (0.01, 0.64) .59
1.66) 115 0.49 (0.11, 1.95) .30
12) 115 506 (46, 4565) .78
115 13.6 (0, 34) .07
t; CB, cord blood; Dx, diagnosis; BU, busfultan; CY, cyclophosphamide;
orming unit-granulocyte macrophage; TX, treatment; ALC, absolute lym-
Biol Blood Marrow Transplant 17:831-840, 2011 839Lymphocyte Recovery after UCBTengraftment may still be occupied with residual
host cells, which might also delay donor lymphocyte
recovery.
Although TRM remains a significant barrier to
the success of UCB transplantation, there have been
very few measures to identify patients at risk for this
complication. For instance, Sorror and colleagues
[40] described the HCT-specific comorbidity index,
but such measures have only been partially validated
in the UCBT setting, because they are predictive for
TRM after myeloablative, but not RIC transplantation
in adult recipients [41].Herewe show that patientswith
hematologic malignancies receiving an MA or RIC
UCBT and fail to achieve an ALC .200  106/L at
day 30 or day 42, respectively, have a significantly infe-
rior OS and PFS. These results may allow for interven-
tions aimed at preventing mortality. Considering that
the majority of deaths after UCB transplantation are
within 180 days and are related to multiorgan failure
and/or infectious complications, day 30 or 42 ALC
may be useful to identify MA or RICUCBT recipients
at risk for early mortality. The findings presented here
also suggest that limiting treatments that delay or
instituting approaches that accelerate lymphocyte re-
covery might have a significant impact on transplant
outcomes. Potential strategies could include improved
antimicrobial prophylaxis, or the use of agents that pro-
mote the recovery and survival of T cells (ie, IL-7 [42])
and/or NK cells (ie, IL-15 [43,44]). Last, agents aimed
at protecting structures involved in de novo T cell
production, including thymic epithelial protectants
and/or stimulants, have considerable promise [45].
Further analyses investigating the impact of ALC
following MA and RIC UCBT for hematologic
malignancies are warranted to confirm these findings.ACKNOWLEDGMENTS
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